Structures by: Drebushchak T. N.
Total: 78
(Rh (N H3)5 Cl) (Pt Br6)
Br6ClH15N5PtRh
Zhurnal Strukturnoi Khimii (Issue-No. from 1981) (2002) 43, 699-705
a=12.013Å b=8.401Å c=15.999Å
α=90° β=91.13° γ=90°
(Rh (N H3)5 Cl)2 (Pt Cl6) Cl2
Cl10H30N10PtRh2
Zhurnal Strukturnoi Khimii (Issue-No. from 1981) (2002) 43, 749-751
a=11.238Å b=7.901Å c=13.419Å
α=90° β=99.48° γ=90°
N-butylammoniun salt of tolbutamide
C4H12N,C12H17N2O3S
CrystEngComm (2013) 15, 18 3582
a=13.5031(6)Å b=11.2985(5)Å c=25.4543(12)Å
α=90.00° β=98.694(4)° γ=90.00°
P-toluenesulfonamide
C7H9NO2S
CrystEngComm (2013) 15, 18 3582
a=5.1562(2)Å b=8.3250(4)Å c=9.8583(7)Å
α=100.801(5)° β=102.284(4)° γ=90.371(3)°
DL-cysteinium semioxalate
C3H8NO2S,C2HO4
CrystEngComm (2012) 14, 18 5943
a=5.66513(16)Å b=9.0127(4)Å c=9.7723(5)Å
α=109.318(4)° β=102.263(3)° γ=100.163(3)°
DL-cysteinium semioxalate
C3H8NO2S,C2HO4
CrystEngComm (2012) 14, 18 5943
a=5.66521(18)Å b=8.9987(4)Å c=9.7696(5)Å
α=109.516(4)° β=102.251(3)° γ=100.096(3)°
DL-cysteinium semioxalate
C3H8NO2S,C2HO4
CrystEngComm (2012) 14, 18 5943
a=5.66264(17)Å b=8.9788(4)Å c=9.7642(4)Å
α=109.682(4)° β=102.236(3)° γ=100.002(3)°
DL-cysteinium semioxalate
C3H8NO2S,C2HO4
CrystEngComm (2012) 14, 18 5943
a=5.66062(16)Å b=8.9394(4)Å c=9.7525(5)Å
α=109.967(4)° β=102.224(3)° γ=99.833(3)°
DL-cysteinium semioxalate
C3H8NO2S,C2HO4
CrystEngComm (2012) 14, 18 5943
a=5.65706(14)Å b=8.9064(4)Å c=9.7446(4)Å
α=110.208(4)° β=102.193(3)° γ=99.702(3)°
DL-cysteinium semioxalate
C3H8NO2S,C2HO4
CrystEngComm (2012) 14, 18 5943
a=5.65949(16)Å b=8.9271(4)Å c=9.7495(4)Å
α=110.093(4)° β=102.220(3)° γ=99.769(3)°
DL-cysteinium semioxalate
C3H8NO2S,C2HO4
CrystEngComm (2012) 14, 18 5943
a=5.65476(17)Å b=8.8702(4)Å c=9.7344(4)Å
α=110.377(4)° β=102.167(3)° γ=99.621(3)°
DL-cysteinium oxalate
C3H8NO2S,0.5(C2O4)
CrystEngComm (2012) 14, 18 5943
a=5.2748(2)Å b=6.6507(3)Å c=10.4397(3)Å
α=86.836(3)° β=76.833(3)° γ=70.093(4)°
DL-cysteinium oxalate
C3H8NO2S,0.5(C2O4)
CrystEngComm (2012) 14, 18 5943
a=5.2705(3)Å b=6.6419(4)Å c=10.4243(5)Å
α=86.895(4)° β=76.869(4)° γ=70.160(5)°
DL-cysteinium oxalate
C3H8NO2S,0.5(C2O4)
CrystEngComm (2012) 14, 18 5943
a=5.2644(3)Å b=6.6233(4)Å c=10.3965(4)Å
α=87.021(4)° β=76.908(4)° γ=70.282(5)°
DL-cysteinium oxalate
C3H8NO2S,0.5(C2O4)
CrystEngComm (2012) 14, 18 5943
a=5.2672(3)Å b=6.6328(4)Å c=10.4111(4)Å
α=86.956(4)° β=76.887(4)° γ=70.227(5)°
DL-cysteinium oxalate
C3H8NO2S,0.5(C2O4)
CrystEngComm (2012) 14, 18 5943
a=5.2615(3)Å b=6.6145(4)Å c=10.3827(4)Å
α=87.080(4)° β=76.924(4)° γ=70.335(5)°
DL-cysteinium oxalate
C3H8NO2S,0.5(C2O4)
CrystEngComm (2012) 14, 18 5943
a=5.2563(3)Å b=6.5980(3)Å c=10.3562(4)Å
α=87.226(4)° β=76.973(4)° γ=70.438(5)°
DL-cysteinium oxalate
C3H8NO2S,0.5(C2O4)
CrystEngComm (2012) 14, 18 5943
a=5.2540(3)Å b=6.5904(3)Å c=10.3425(4)Å
α=87.327(4)° β=77.009(4)° γ=70.477(5)°
DL-cysteinium oxalate
C3H8NO2S,0.5(C2O4)
CrystEngComm (2012) 14, 18 5943
a=5.2521(2)Å b=6.5844(3)Å c=10.3311(2)Å
α=87.440(3)° β=77.032(3)° γ=70.505(3)°
N-Acetyl-L-Cysteine
C5H9NO3S
CrystEngComm (2012) 14, 18 5943
a=5.08996(15)Å b=5.8843(2)Å c=6.5214(2)Å
α=96.452(3)° β=103.859(3)° γ=102.076(3)°
N-Acetyl-L-Cysteine
C5H9NO3S
CrystEngComm (2012) 14, 18 5943
a=5.07618(15)Å b=5.8583(2)Å c=6.5043(2)Å
α=96.300(3)° β=103.661(3)° γ=102.203(3)°
N-Acetyl-L-Cysteine
C5H9NO3S
CrystEngComm (2012) 14, 18 5943
a=5.06381(14)Å b=5.83621(18)Å c=6.4864(2)Å
α=96.162(3)° β=103.409(3)° γ=102.331(3)°
N-Acetyl-L-Cysteine
C5H9NO3S
CrystEngComm (2012) 14, 18 5943
a=5.04324(14)Å b=5.80332(17)Å c=6.4627(2)Å
α=95.944(3)° β=103.086(3)° γ=102.516(3)°
N-Acetyl-L-Cysteine
C5H9NO3S
CrystEngComm (2012) 14, 18 5943
a=5.05300(17)Å b=5.81773(18)Å c=6.4717(2)Å
α=96.051(3)° β=103.212(3)° γ=102.439(3)°
DL-cysteinium semioxalate
C3H8NO2S,C2HO4
CrystEngComm (2012) 14, 18 5943
a=5.66107(17)Å b=8.9574(5)Å c=9.7578(5)Å
α=109.831(5)° β=102.228(4)° γ=99.913(3)°
DL-cysteinium oxalate
C3H8NO2S,0.5(C2O4)
CrystEngComm (2012) 14, 18 5943
a=5.2589(3)Å b=6.6056(4)Å c=10.3687(4)Å
α=87.155(4)° β=76.947(4)° γ=70.385(5)°
Tolbutamide form I^H^
C12H18N2O3S
CrystEngComm (2016) 18, 30 5736
a=20.7500(15)Å b=7.9160(7)Å c=9.0580(5)Å
α=90° β=90° γ=90°
Tolbutamide form I^L^
C12H18N2O3S
CrystEngComm (2016) 18, 30 5736
a=20.2133(6)Å b=7.8233(2)Å c=9.0717(2)Å
α=90° β=90° γ=90°
Tolbutamide form I^L^
C12H18N2O3S
CrystEngComm (2016) 18, 30 5736
a=19.7525(3)Å b=7.7998(1)Å c=9.0583(1)Å
α=90° β=90° γ=90°
Tolbutamide form I^L^
C12H18N2O3S
CrystEngComm (2016) 18, 30 5736
a=19.4331(3)Å b=7.8010(1)Å c=9.0277(1)Å
α=90° β=90° γ=90°
Tolbutamide form II
C12H18N2O3S
CrystEngComm (2016) 18, 30 5736
a=9.0256(2)Å b=17.1443(5)Å c=17.7904(5)Å
α=90° β=94.268(3)° γ=90°
Chlorpropamide, α-form
C10H13ClN2O3S
Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials (2013) 69, 1 77
a=26.5733(18)Å b=4.7178(2)Å c=8.6406(2)Å
α=90.00° β=90.00° γ=90.00°
Chlorpropamide, α-form
C10H13ClN2O3S
Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials (2013) 69, 1 77
a=26.573(2)Å b=4.8587(2)Å c=8.8165(4)Å
α=90.00° β=90.00° γ=90.00°
Chlorpropamide, α-form
C10H13ClN2O3S
Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials (2013) 69, 1 77
a=26.605(2)Å b=4.6688(2)Å c=8.5711(3)Å
α=90.00° β=90.00° γ=90.00°
Chlorpropamide, α-form
C10H13ClN2O3S
Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials (2013) 69, 1 77
a=26.6068(19)Å b=4.6576(2)Å c=8.5556(2)Å
α=90.00° β=90.00° γ=90.00°
Chlorpropamide, α^II^-form
C10H13ClN2O3S
Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials (2013) 69, 1 77
a=25.602(3)Å b=4.6340(2)Å c=8.8525(4)Å
α=99.109(4)° β=90.00° γ=90.00°
Chlorpropamide, α^II^-form
C10H13ClN2O3S
Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials (2013) 69, 1 77
a=25.522(6)Å b=4.6023(7)Å c=8.8298(15)Å
α=99.477(14)° β=90.00° γ=90.00°
Tolazamide
C14H21N3O3S
Acta Crystallographica Section C (2019) 75, 5 598-608
a=6.3453(3)Å b=9.1929(5)Å c=13.4917(7)Å
α=79.103(5)° β=87.266(4)° γ=85.857(5)°
Tolazamide
C14H21N3O3S
Acta Crystallographica Section C (2019) 75, 5 598-608
a=6.3506(6)Å b=9.2241(9)Å c=13.4984(13)Å
α=79.091(8)° β=87.215(8)° γ=85.815(8)°
Tolazamide
C14H21N3O3S
Acta Crystallographica Section C (2019) 75, 5 598-608
a=6.3346(3)Å b=9.1641(5)Å c=13.4642(7)Å
α=79.222(4)° β=87.305(4)° γ=85.936(4)°
Tolazamide
C14H21N3O3S
Acta Crystallographica Section C (2019) 75, 5 598-608
a=6.3186(5)Å b=9.1502(8)Å c=13.4244(11)Å
α=79.314(7)° β=87.303(7)° γ=85.948(7)°
Tolazamide
C14H21N3O3S
Acta Crystallographica Section C (2019) 75, 5 598-608
a=6.3064(5)Å b=9.1298(7)Å c=13.3984(11)Å
α=79.397(7)° β=87.344(7)° γ=85.986(6)°
Tolazamide
C14H21N3O3S
Acta Crystallographica Section C (2019) 75, 5 598-608
a=6.2891(3)Å b=9.0960(4)Å c=13.3659(5)Å
α=79.436(4)° β=87.381(3)° γ=86.026(4)°
Tolazamide
C14H21N3O3S
Acta Crystallographica Section C (2019) 75, 5 598-608
a=6.2586(2)Å b=9.0748(4)Å c=13.3249(5)Å
α=79.432(3)° β=87.442(3)° γ=85.975(3)°
Tolazamide
C14H21N3O3S
Acta Crystallographica Section C (2019) 75, 5 598-608
a=6.2738(3)Å b=9.0824(4)Å c=13.3414(5)Å
α=79.449(4)° β=87.415(3)° γ=86.013(4)°
Tolazamide
C14H21N3O3S
Acta Crystallographica Section C (2019) 75, 5 598-608
a=6.4468(3)Å b=9.0141(5)Å c=13.4850(7)Å
α=82.360(4)° β=85.368(4)° γ=85.553(4)°
Tolazamide
C14H21N3O3S
Acta Crystallographica Section C (2019) 75, 5 598-608
a=6.3091(10)Å b=8.9270(15)Å c=13.576(3)Å
α=81.882(16)° β=86.073(16)° γ=85.167(13)°
Tolazamide
C14H21N3O3S
Acta Crystallographica Section C (2019) 75, 5 598-608
a=6.3358(8)Å b=8.9455(11)Å c=13.5482(15)Å
α=81.976(10)° β=85.919(10)° γ=85.273(10)°
Chlorpropamide, ε`-form
C10H13ClN2O3S
Acta Crystallographica Section B (2009) 65, 6 770-781
a=26.4353(19)Å b=5.1398(4)Å c=9.0845(6)Å
α=90.00° β=90.00° γ=90.00°
Chlorpropamide, ε-form
C10H13ClN2O3S
Acta Crystallographica Section B (2009) 65, 6 770-781
a=19.805(2)Å b=7.3500(7)Å c=9.1295(9)Å
α=90.00° β=90.00° γ=90.00°
Chlorpropamide, ε`-form
C10H13ClN2O3S
Acta Crystallographica Section B (2009) 65, 6 770-781
a=26.455(4)Å b=5.1924(9)Å c=9.1219(11)Å
α=90.00° β=90.00° γ=90.00°
Chlorpropamide, α-form
C10H13ClN2O3S
Acta Crystallographica Section B (2009) 65, 6 770-781
a=26.657(6)Å b=5.0938(16)Å c=8.9941(18)Å
α=90.00° β=90.00° γ=90.00°
Chlorpropamide, α-form
C10H13ClN2O3S
Acta Crystallographica Section B (2009) 65, 6 770-781
a=26.675(5)Å b=5.1438(14)Å c=9.0370(16)Å
α=90.00° β=90.00° γ=90.00°
Chlorpropamide, α-form
C10H13ClN2O3S
Acta Crystallographica Section B (2009) 65, 6 770-781
a=26.673(6)Å b=5.2296(19)Å c=9.088(2)Å
α=90.00° β=90.00° γ=90.00°
Chlorpropamide, β^II^-form
C10H13ClN2O3S
Acta Crystallographica Section B (2011) 67, 2 163-176
a=14.5882(5)Å b=9.2584(2)Å c=19.1532(6)Å
α=90.00° β=93.260(3)° γ=90.00°
Chlorpropamide, β^III^-form
C10H13ClN2O3S
Acta Crystallographica Section B (2011) 67, 2 163-176
a=28.4475(12)Å b=9.2322(3)Å c=19.2298(7)Å
α=90.00° β=95.562(4)° γ=90.00°
Chlorpropamide, α-form
C10H13ClN2O3S
Acta Crystallographica Section B (2013) 69, 1 77-85
a=26.573(2)Å b=4.8587(2)Å c=8.8165(4)Å
α=90.00° β=90.00° γ=90.00°
Chlorpropamide, α-form
C10H13ClN2O3S
Acta Crystallographica Section B (2013) 69, 1 77-85
a=26.5733(18)Å b=4.7178(2)Å c=8.6406(2)Å
α=90.00° β=90.00° γ=90.00°
Chlorpropamide, α-form
C10H13ClN2O3S
Acta Crystallographica Section B (2013) 69, 1 77-85
a=26.605(2)Å b=4.6688(2)Å c=8.5711(3)Å
α=90.00° β=90.00° γ=90.00°
Chlorpropamide, α-form
C10H13ClN2O3S
Acta Crystallographica Section B (2013) 69, 1 77-85
a=26.6068(19)Å b=4.6576(2)Å c=8.5556(2)Å
α=90.00° β=90.00° γ=90.00°
Chlorpropamide, α^II^-form
C10H13ClN2O3S
Acta Crystallographica Section B (2013) 69, 1 77-85
a=25.602(3)Å b=4.6340(2)Å c=8.8525(4)Å
α=99.109(4)° β=90.00° γ=90.00°
Chlorpropamide, α^II^-form
C10H13ClN2O3S
Acta Crystallographica Section B (2013) 69, 1 77-85
a=25.522(6)Å b=4.6023(7)Å c=8.8298(15)Å
α=99.477(14)° β=90.00° γ=90.00°
4-Benzylcarbamoyl-1-methylpyridin-1-ium iodide
C14H15N2O,I
Acta Crystallographica Section E (2017) 73, 7 967-970
a=9.2867(2)Å b=10.8741(2)Å c=14.3038(3)Å
α=90° β=90° γ=90°
Sulfathiazole adduct with pyridine, tetragonal form
C9H9N3O2S2,C5H5N
Acta Crystallographica Section E (2006) 62, 7 o2707-o2709
a=8.385(3)Å b=9.272(2)Å c=20.704(8)Å
α=90.00° β=100.10(3)° γ=90.00°
Sulfathiazole adduct with pyridine, tetragonal form
C9H9N3O2S2,C5H5N
Acta Crystallographica Section E (2006) 62, 7 o2669-o2671
a=8.670(2)Å b=8.670(2)Å c=20.927(10)Å
α=90.00° β=90.00° γ=90.00°
Glycine
C2H5NO2
Acta Crystallographica Section E (2002) 58, 6 o634-o636
a=5.0935(11)Å b=6.274(2)Å c=5.3847(12)Å
α=90.00° β=113.19(2)° γ=90.00°
L-serine III
C3H7NO3
Acta Crystallographica Section E (2006) 62, 9 o4052-o4054
a=5.6117(9)Å b=6.556(2)Å c=9.5321(12)Å
α=90.00° β=90.00° γ=90.00°
Chlorpropamide
C10H13ClN2O3S
Acta Crystallographica Section E (2006) 62, 10 o4393-o4395
a=14.777(3)Å b=9.316(4)Å c=19.224(5)Å
α=90.00° β=90.00° γ=90.00°
DL-cysteinium hemioxalate
2(C3H8NO2S),C2O42
Acta Crystallographica Section C (2008) 64, 6 o313-o315
a=5.2779(6)Å b=6.6526(7)Å c=10.4424(15)Å
α=86.840(11)° β=76.844(11)° γ=70.097(10)°
Chlorpropamide
C10H13ClN2O3S
Acta Crystallographica Section C (2007) 63, 6 o355-o357
a=6.126(2)Å b=8.941(6)Å c=12.020(4)Å
α=90.00° β=99.68(3)° γ=90.00°
Chlorpropamide, δ-form
C10H13ClN2O3S
Acta Crystallographica Section C (2008) 64, 12 o623-o625
a=9.3198(4)Å b=10.3218(3)Å c=26.2663(10)Å
α=90.00° β=90.00° γ=90.00°
Chlorpropamide, ε-form
C10H13ClN2O3S
Acta Crystallographica Section C (2008) 64, 12 o623-o625
a=19.9121(10)Å b=7.3459(4)Å c=9.1384(4)Å
α=90.00° β=90.00° γ=90.00°
Glycinium semi-malonate
C2H6NO2,C3H3O4
Acta Crystallographica Section C (2011) 67, 8 o297-o300
a=10.1431(19)Å b=8.1729(11)Å c=9.260(2)Å
α=90.00° β=101.879(16)° γ=90.00°
Glutaric acid--glycine (1/1)
C2H5NO2,C5H8O4
Acta Crystallographica Section C (2011) 67, 8 o297-o300
a=4.8954(4)Å b=20.8944(14)Å c=10.8462(8)Å
α=90.00° β=120.648(6)° γ=90.00°
Piroxicam Benzoate
C22H17N3O5S
Acta Crystallographica Section C (2006) 62, 7 o429-o431
a=11.106(3)Å b=16.5606(16)Å c=12.0351(18)Å
α=90° β=111.463(12)° γ=90°
Tolazamide
C14H21N3O3S
Acta Crystallographica Section C (2019) 75, 5 598-608
a=6.2433(2)Å b=9.0724(4)Å c=13.3119(5)Å
α=79.359(4)° β=87.461(3)° γ=85.933(3)°
Tolazamide
C14H21N3O3S
Acta Crystallographica Section C (2019) 75, 5 598-608
a=6.4948(3)Å b=9.0520(4)Å c=13.4605(6)Å
α=82.467(4)° β=85.251(4)° γ=85.836(4)°
Tolazamide
C14H21N3O3S
Acta Crystallographica Section C (2019) 75, 5 598-608
a=6.3939(3)Å b=8.9809(4)Å c=13.5213(7)Å
α=82.129(4)° β=85.602(4)° γ=85.341(4)°